What's in MEDA Pharma GmbH & Co. KG's pipeline?

MEDA Pharma GmbH & Co. KG has 11 drugs in our index: 2 marketed, 0 filed, 1 in Phase 3, 5 in Phase 2, 2 in Phase 1.

Which companies overlap with MEDA Pharma GmbH & Co. KG's portfolio?

Top competitors by shared drug class: Apotex Inc., Charles University, Czech Republic, Elion Therapeutics, Inc., Graceway Pharmaceuticals, LLC, Hippocration General Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/meda-pharma-gmbh-co-kg.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

MEDA Pharma GmbH & Co. KG — Portfolio Competitive Intelligence Brief

MEDA Pharma GmbH & Co. KG pipeline: 2 marketed, 0 filed, 1 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 5 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Flecainide controlled release	Flecainide controlled release	marketed	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)	Cardiovascular
fluticasone propionate nasal spray + loratadine	fluticasone propionate nasal spray + loratadine	marketed	Corticosteroid + antihistamine combination	Glucocorticoid receptor (fluticasone); H1-histamine receptor (loratadine)	Allergy/Immunology
Aldara (Imiquimod)	Aldara (Imiquimod)	phase 3	TLR7 agonist	TLR7 (Toll-like receptor 7)	Dermatology, Oncology, Immunology

Therapeutic area mix

Respiratory · 2
Allergy/Immunology · 1
Cardiovascular · 1
Dermatology, Oncology, Immunology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Apotex Inc. · 1 shared drug class
Charles University, Czech Republic · 1 shared drug class
Elion Therapeutics, Inc. · 1 shared drug class
Graceway Pharmaceuticals, LLC · 1 shared drug class
Hippocration General Hospital · 1 shared drug class
Medical University of Graz · 1 shared drug class
Medical University of Vienna · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MEDA Pharma GmbH & Co. KG:

Cite this brief

Drug Landscape (2026). MEDA Pharma GmbH & Co. KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/meda-pharma-gmbh-co-kg. Accessed 2026-05-16.